Reviva Posts Narrower Q2 Loss, $19.9M Cash, and New Patent Strategy to Extend Brilaroxazine Exclusivity to 2046

summarizeSummary

Reviva reported a narrower Q2 net loss of $2.4M, cash of $19.9M, and a new patent strategy to extend brilaroxazine exclusivity to 2046, with FDA feedback expected Q4 2026 and RECOVER-2 enrollment targeted for 1H 2027.

check_boxKey Events · Earnings and Guidance · RVPH

• Q2 Net Loss Narrows to $2.4M

  Net loss of $2.4 million ($0.19/share) for Q2 2026, down from $6.1 million ($2.40/share) in Q2 2025, driven by lower R&D and G&A expenses.

• Cash Position Strengthens to $19.9M

  Cash and cash equivalents totaled $19.9 million as of June 30, 2026, up from $14.4 million at December 31, 2025, providing runway into 2027.

• New Patent Application Targets 2046 Exclusivity

  Filed a U.S. composition of matter patent application for a new form of brilaroxazine, seeking accelerated review to extend patent life and commercial exclusivity through 2046.

• FDA Feedback Expected Q4 2026

  FDA feedback on using the new brilaroxazine formulation in the RECOVER-2 trial and NDA is expected in Q4 2026, with a bioequivalence study planned to start in Q4 2026.

auto_awesomeAnalysis · RVPH · Life Sciences

The Q2 2026 results show a sharply reduced net loss of $2.4 million versus $6.1 million a year ago, driven by lower R&D and G&A spending. Cash stands at $19.9 million, up from $14.4 million at year-end, providing runway into 2027. A new composition of matter patent application for a new form of brilaroxazine seeks accelerated review to extend commercial exclusivity through 2046. FDA feedback on using the new formulation in the RECOVER-2 trial and NDA is expected in Q4 2026, with patient enrollment targeted for 1H 2027 subject to additional financing. The stock trades on OTCQB after Nasdaq delisting, and the company reiterates a going concern warning, making the cash position and financing-dependent milestones critical for investors.